102561-42-2 Usage
Description
3-Fluoro-4-methylphenyl isocyanate, also known as 2-fluoro-4-isocyanato-1-methylbenzene, is an organic building block that features an isocyanate group. 3-FLUORO-4-METHYLPHENYL ISOTHIOCYANATE is significant in the field of organic chemistry due to its potential applications in the synthesis of various organic compounds.
Uses
Used in Pharmaceutical Industry:
3-Fluoro-4-methylphenyl isocyanate is used as a synthetic intermediate for the development of 3-fluoro analogues of 5-(acetamido-methyl)oxazolidinones. These analogues are of interest in the pharmaceutical industry due to their potential therapeutic properties and applications in the treatment of various medical conditions.
In the synthesis of 3-fluoro analogues, 3-Fluoro-4-methylphenyl isocyanate serves as a key component, allowing for the creation of new molecules with potentially improved pharmacological profiles. The introduction of the fluorine atom and the isocyanate group in the molecule can lead to enhanced biological activity, selectivity, and stability, which are crucial factors in drug development.
Overall, 3-Fluoro-4-methylphenyl isocyanate plays a vital role in the pharmaceutical industry as a building block for the synthesis of novel compounds with potential therapeutic applications. Its unique structure and reactivity make it a valuable asset in the ongoing quest to discover new and effective treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 102561-42-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,2,5,6 and 1 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 102561-42:
(8*1)+(7*0)+(6*2)+(5*5)+(4*6)+(3*1)+(2*4)+(1*2)=82
82 % 10 = 2
So 102561-42-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H6FNO/c1-6-4-7(10-5-11)2-3-8(6)9/h2-4H,1H3
102561-42-2Relevant articles and documents
Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
Lakkaniga, Naga Rajiv,Zhang, Lingtian,Belachew, Binyam,Gunaganti, Naresh,Frett, Brendan,Li, Hong-yu
, (2020)
Aurora Kinase B is a serine-threonine kinase known to be overexpressed in several cancers, with no inhibitors approved for clinical use. Herein, we present the discovery and optimization of a series of novel quinazoline-based Aurora Kinase B inhibitors. The lead inhibitor SP-96 shows sub-nanomolar potency in Aurora B enzymatic assays (IC50 = 0.316 ± 0.031 nM). We identified the important pharmacophore features resulting in selectivity against receptor tyrosine kinases. Particularly, SP-96 shows >2000 fold selectivity against FLT3 and KIT which is important for normal hematopoiesis. This could diminish the adverse effect of neutropenia reported in the clinical trials of the Aurora B inhibitor Barasertib, which inhibits FLT3 and KIT in addition to Aurora B. Enzyme kinetics of SP-96 shows non-ATP-competitive inhibition which makes it a first-in-class inhibitor. Further, SP-96 shows selective growth inhibition in NCI60 screening, including inhibition of MDA-MD-468, a Triple Negative Breast Cancer cell line.
ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND
-
Page/Page column 45, (2010/02/14)
The invention relates to the substituted imidazoles of formula (I) and to methods for producing the same, to their use in the treatment and/or prophylaxis of diseases and to their use for producing drugs for use in the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, especially against cytomegaloviruses.